Company intelligence / Profile preview
NETRIS Pharma
Lyon, Auvergne-Rhône-Alpes, Francenetrispharma.com ↗
- Ownership
- Private
- Employees
- ~16
- Development stage
- Phase 1
01
Overview
NETRIS Pharma’s lead asset NP137, a first-in-class humanized monoclonal antibody targeting netrin‑1, has demonstrated an excellent safety profile and promising anti-tumoral activity across several solid tumor indications. As of April 2025, positive interim Phase II results were announced for NP137 in combination with anti-PD(L)1 therapy. The company also received FDA Orphan Drug Designation for pancreatic cancer treatment with NP137.
- Therapeutic areas
- Women's HealthOncology
- Modalities
- Monoclonal antibodies (mAbs)Humanized monoclonal antibody (IgG1)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
MSD (Merck & Co.)ORANOCentre Léon Bérard
Beyond the preview
Go deeper on NETRIS Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NETRIS Pharma.